D.A. Davidson & CO. lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 147.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,911 shares of the medical research company’s stock after buying an additional 14,263 shares during the quarter. D.A. Davidson & CO.’s holdings in Edwards Lifesciences Corporation were worth $2,827,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in EW. Ithaka Group LLC raised its stake in Edwards Lifesciences Corporation by 1.0% during the second quarter. Ithaka Group LLC now owns 133,902 shares of the medical research company’s stock valued at $15,833,000 after purchasing an additional 1,290 shares in the last quarter. UBS Asset Management Americas Inc. raised its stake in Edwards Lifesciences Corporation by 6.4% during the second quarter. UBS Asset Management Americas Inc. now owns 611,062 shares of the medical research company’s stock valued at $72,252,000 after purchasing an additional 36,936 shares in the last quarter. Nicholas Investment Partners LP purchased a new stake in Edwards Lifesciences Corporation during the second quarter valued at $5,904,000. New York State Common Retirement Fund raised its stake in Edwards Lifesciences Corporation by 10.4% during the second quarter. New York State Common Retirement Fund now owns 509,200 shares of the medical research company’s stock valued at $60,208,000 after purchasing an additional 47,799 shares in the last quarter. Finally, Artisan Partners Limited Partnership raised its stake in Edwards Lifesciences Corporation by 90.6% during the second quarter. Artisan Partners Limited Partnership now owns 1,278,532 shares of the medical research company’s stock valued at $151,174,000 after purchasing an additional 607,784 shares in the last quarter. 82.08% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Shares Bought by D.A. Davidson & CO.” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/22/edwards-lifesciences-corporation-ew-shares-bought-by-d-a-davidson-co.html.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $117.15, for a total value of $656,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Mussallem sold 32,900 shares of Edwards Lifesciences Corporation stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 182,501 shares of company stock valued at $20,847,236. 2.13% of the stock is currently owned by corporate insiders.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 110.185 on Friday. The company has a 50-day moving average of $113.80 and a 200-day moving average of $109.37. The stock has a market capitalization of $23.27 billion, a price-to-earnings ratio of 33.420 and a beta of 0.64. Edwards Lifesciences Corporation has a 1-year low of $81.12 and a 1-year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period last year, the company earned $0.76 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.

A number of equities research analysts recently issued reports on EW shares. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a research note on Monday, August 28th. BMO Capital Markets reaffirmed a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences Corporation in a research note on Friday, September 1st. Barclays PLC upped their price target on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, July 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 price target on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Finally, Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price target on the stock in a research note on Tuesday, July 18th. Six investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $120.75.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.